Vidaza 100 mg, 1 vial (Azacitidine 100 mg) by Bristol Myers Squibb.
Indications: Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults not eligible for stem cell transplantation.
Administration: Subcutaneous injection of 75 mg/m² daily for 7 days, every 28 days.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Bristol Myers Squibb (Celgene) |
| Active ingredient | Azacitidine 100 mg — hypomethylating agent. |
| Strength & pack | 1 vial of powder. |
| Form | Powder for suspension for injection |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |